A new recombinant virus system for the study of HIV-1 entry and inhibition

Francois Roman; Wim Ammerlaan; Jean Marc Plesseria; Sabrina Deroo; Claude P. Muller; Vic Arendt; Francois Schneider; Robert Hemmer; Jean Claude Schmit

doi:10.1016/j.jviromet.2005.07.005

A new recombinant virus system for the study of HIV-1 entry and inhibition

Francois Roman^*, Wim Ammerlaan, Jean Marc Plesseria, Sabrina Deroo, Claude P. Muller, Vic Arendt, Francois Schneider, Robert Hemmer, Jean Claude Schmit

^*Corresponding author for this work

Department of Infection and Immunity

Research output: Contribution to journal › Article › Research › peer-review

3 Citations (Scopus)

Abstract

The construction is described of a HIV-1 proviral, eGFP-tagged plasmid that allows for the recombination of any selected env gene without the use of restriction enzymes and for the quantitation of the infection by the recombinant virus using flow cytometry. The system was tested showing that an isoleucine to valine substitution at residue position 37 of the HIV-1 gp41 impairs the fitness of the virus but does not lead by itself to T-20 resistance.

Original language	English
Pages (from-to)	99-104
Number of pages	6
Journal	Journal of Virological Methods
Volume	131
Issue number	1
DOIs	https://doi.org/10.1016/j.jviromet.2005.07.005
Publication status	Published - Jan 2006

Access to Document

10.1016/j.jviromet.2005.07.005

Cite this

@article{1aed5393535c4df0a619e3cf8b46a689,

title = "A new recombinant virus system for the study of HIV-1 entry and inhibition",

abstract = "The construction is described of a HIV-1 proviral, eGFP-tagged plasmid that allows for the recombination of any selected env gene without the use of restriction enzymes and for the quantitation of the infection by the recombinant virus using flow cytometry. The system was tested showing that an isoleucine to valine substitution at residue position 37 of the HIV-1 gp41 impairs the fitness of the virus but does not lead by itself to T-20 resistance.",

author = "Francois Roman and Wim Ammerlaan and Plesseria, {Jean Marc} and Sabrina Deroo and Muller, {Claude P.} and Vic Arendt and Francois Schneider and Robert Hemmer and Schmit, {Jean Claude}",

note = "Funding Information: This work was supported by the {\textquoteleft}Fondation Recherche sur le SIDA{\textquoteright} and the {\textquoteleft}Centre de Recherche Publique-Sant{\'e}{\textquoteright} (CRP-Sant{\'e}), Luxembourg, and in part by a GlaxoSmithKline grant awarded by the Belgian society for the Study of Infectiology and Clinical Microbiology (SBIMC-BVIKM). F.R. acknowledges a grant (BFR99/003) from the {\textquoteleft}Minist{\`e}re de la Culture, de l{\textquoteright}Enseignement Sup{\'e}rieur et de la Recherche{\textquoteright}, Luxembourg (1999–2002). The following reagents were obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH: pNL4-3 from Dr. Malcolm Martin and HXB2-env from Dr. Kathleen Page and Dr. Dan Littman.",

year = "2006",

month = jan,

doi = "10.1016/j.jviromet.2005.07.005",

language = "English",

volume = "131",

pages = "99--104",

journal = "Journal of Virological Methods",

issn = "0166-0934",

publisher = "Elsevier",

number = "1",

}

TY - JOUR

T1 - A new recombinant virus system for the study of HIV-1 entry and inhibition

AU - Roman, Francois

AU - Ammerlaan, Wim

AU - Plesseria, Jean Marc

AU - Deroo, Sabrina

AU - Muller, Claude P.

AU - Arendt, Vic

AU - Schneider, Francois

AU - Hemmer, Robert

AU - Schmit, Jean Claude

N1 - Funding Information: This work was supported by the ‘Fondation Recherche sur le SIDA’ and the ‘Centre de Recherche Publique-Santé’ (CRP-Santé), Luxembourg, and in part by a GlaxoSmithKline grant awarded by the Belgian society for the Study of Infectiology and Clinical Microbiology (SBIMC-BVIKM). F.R. acknowledges a grant (BFR99/003) from the ‘Ministère de la Culture, de l’Enseignement Supérieur et de la Recherche’, Luxembourg (1999–2002). The following reagents were obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH: pNL4-3 from Dr. Malcolm Martin and HXB2-env from Dr. Kathleen Page and Dr. Dan Littman.

PY - 2006/1

Y1 - 2006/1

N2 - The construction is described of a HIV-1 proviral, eGFP-tagged plasmid that allows for the recombination of any selected env gene without the use of restriction enzymes and for the quantitation of the infection by the recombinant virus using flow cytometry. The system was tested showing that an isoleucine to valine substitution at residue position 37 of the HIV-1 gp41 impairs the fitness of the virus but does not lead by itself to T-20 resistance.

AB - The construction is described of a HIV-1 proviral, eGFP-tagged plasmid that allows for the recombination of any selected env gene without the use of restriction enzymes and for the quantitation of the infection by the recombinant virus using flow cytometry. The system was tested showing that an isoleucine to valine substitution at residue position 37 of the HIV-1 gp41 impairs the fitness of the virus but does not lead by itself to T-20 resistance.

UR - http://www.scopus.com/inward/record.url?scp=28844489915&partnerID=8YFLogxK

UR - https://pubmed.ncbi.nlm.nih.gov/16111774

U2 - 10.1016/j.jviromet.2005.07.005

DO - 10.1016/j.jviromet.2005.07.005

M3 - Article

C2 - 16111774

AN - SCOPUS:28844489915

SN - 0166-0934

VL - 131

SP - 99

EP - 104

JO - Journal of Virological Methods

JF - Journal of Virological Methods

IS - 1

ER -

A new recombinant virus system for the study of HIV-1 entry and inhibition

Abstract

Access to Document

Other files and links

Fingerprint

Cite this